Jonas Bønnelykke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonas Bønnelykke has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anatoly B. Rosenfeld
Centre for Medical Radiation Physics, University of Wollongong
1 shared publication - Anders Tobias Frederiksen
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark
1 shared publication Anirban Samanta
Department of Chemistry and Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus, Denmark
1 shared publicationBrita Singers Sørensen
Danish Centre for Particle Therapy, Aarhus University Hospital, Palle Juul-Jensens Boulevard 25, Aarhus, 8200, DENMARK
1 shared publicationCecilie Schmidt Herø
Department of Chemistry, Aarhus University, Langelandsgade 140, Aarhus, 8000, Denmark
1 shared publicationHans Christian D. Hammershøj
Carbon Dioxide Activation Center (CADIAC), Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark
1 shared publication
Latest Publications
- Open Access
- 18 February 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (5) , 055008
In-vitro and microdosimetric study of proton boron capture therapy and neutron capture enhanced proton therapy
Objective. The clinical advantage of proton therapy, compared to other types of irradiations, lies in its reduced dose to normal tissue. Still, proton therapy faces challenges of normal tissue toxicity and radioresistant tumors. To combat these challenges, proton boron capture therapy (PBCT) and neutron capture enhanced particle therapy (NCEPT) were proposed to introduce high-LET radiation in the target volume. Approach. In this work, we performed in-vitro experiments with a V79 cell line to validate PBCT and introduced a novel approach to use NCEPT in proton therapy. We quantified the effectiveness of PBCT and NCEPT with microdosimetric measurements, Monte-Carlo simulations and microdosimetric kinetic RBE model (MKM). Main results. No RBE increase was observed for PBCT. With the use of a tungsten spallation source, enough neutrons were generated in the incoming proton beam to measure significant neutron capture in the microdosimeter. However, no significant increase of RBE was detected when conventional in vitro protocol was followed. The resulting cell deactivation based RBE for NCEPT was found to be heavily dependent on which criteria was used to determine surviving colonies. Significance. PBCT and NCEPT are two proposed treatment modalities that may have the potential to expand the cases in which proton therapy can be beneficial. Understanding the scope of these treatment methods and developing measurement protocols to evaluate and understand their RBE impact are the first step to quantify their potential in clinical context.
- 18 February 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (5) , 055008
Open AccessIn-vitro and microdosimetric study of proton boron capture therapy and neutron capture enhanced proton therapy
Objective. The clinical advantage of proton therapy, compared to other types of irradiations, lies in its reduced dose to normal tissue. Still, proton therapy faces challenges of normal tissue toxicity and radioresistant tumors. To combat these challenges, proton boron capture therapy (PBCT) and neutron capture enhanced particle therapy (NCEPT) were proposed to introduce high-LET radiation in the target volume. Approach. In this work, we performed in-vitro experiments with a V79 cell line to validate PBCT and introduced a novel approach to use NCEPT in proton therapy. We quantified the effectiveness of PBCT and NCEPT with microdosimetric measurements, Monte-Carlo simulations and microdosimetric kinetic RBE model (MKM). Main results. No RBE increase was observed for PBCT. With the use of a tungsten spallation source, enough neutrons were generated in the incoming proton beam to measure significant neutron capture in the microdosimeter. However, no significant increase of RBE was detected when conventional in vitro protocol was followed. The resulting cell deactivation based RBE for NCEPT was found to be heavily dependent on which criteria was used to determine surviving colonies. Significance. PBCT and NCEPT are two proposed treatment modalities that may have the potential to expand the cases in which proton therapy can be beneficial. Understanding the scope of these treatment methods and developing measurement protocols to evaluate and understand their RBE impact are the first step to quantify their potential in clinical context.
- 10 July 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (29) , 20141-20146
Self-Assembly of Ultrasmall 3D Architectures of (l)-Acyclic Threoninol Nucleic Acids with High Thermal and Serum Stability
The primary challenge of implementing DNA nanostructures in biomedical applications lies in their vulnerability to nuclease degradation and variations in ionic strength. Furthermore, the size minimization of DNA and RNA nanostructures is limited by the stability of the DNA and RNA duplexes. This study presents a solution to these problems through the use of acyclic (l)-threoninol nucleic acid (aTNA), an artificial acyclic nucleic acid, which offers enhanced resilience under physiological conditions. The high stability of homo aTNA duplexes enables the design of durable nanostructures with dimensions below 5 nm, previously unattainable due to the inherent instability of DNA structures. The assembly of a stable aTNA-based 3D cube and pyramid that involves an i-motif formation is demonstrated. In particular, the cube outperforms its DNA-based counterparts in terms of stability. We furthermore demonstrate the successful attachment of a nanobody to the aTNA cube using the favorable triplex formation of aTNA with ssDNA. The selective in vitro binding capability to human epidermal growth factor receptor 2 is demonstrated. The presented research presents the use of aTNA for the creation of smaller durable nanostructures for future medical applications. It also introduces a new method for attaching payloads to these structures, enhancing their utility in targeted therapies.
- 10 July 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (29) , 20141-20146
Self-Assembly of Ultrasmall 3D Architectures of (l)-Acyclic Threoninol Nucleic Acids with High Thermal and Serum Stability
The primary challenge of implementing DNA nanostructures in biomedical applications lies in their vulnerability to nuclease degradation and variations in ionic strength. Furthermore, the size minimization of DNA and RNA nanostructures is limited by the stability of the DNA and RNA duplexes. This study presents a solution to these problems through the use of acyclic (l)-threoninol nucleic acid (aTNA), an artificial acyclic nucleic acid, which offers enhanced resilience under physiological conditions. The high stability of homo aTNA duplexes enables the design of durable nanostructures with dimensions below 5 nm, previously unattainable due to the inherent instability of DNA structures. The assembly of a stable aTNA-based 3D cube and pyramid that involves an i-motif formation is demonstrated. In particular, the cube outperforms its DNA-based counterparts in terms of stability. We furthermore demonstrate the successful attachment of a nanobody to the aTNA cube using the favorable triplex formation of aTNA with ssDNA. The selective in vitro binding capability to human epidermal growth factor receptor 2 is demonstrated. The presented research presents the use of aTNA for the creation of smaller durable nanostructures for future medical applications. It also introduces a new method for attaching payloads to these structures, enhancing their utility in targeted therapies.
- 6 February 2023
- Published by Springer Nature in Nature Synthesis
- Vol. 2 (3) , 243-250
Multi-carbon labelling of active pharmaceutical ingredients enabled by a three-gas surrogate hydroformylation
- 6 February 2023
- Published by Springer Nature in Nature Synthesis
- Vol. 2 (3) , 243-250
Multi-carbon labelling of active pharmaceutical ingredients enabled by a three-gas surrogate hydroformylation